Navigation Links
Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease
Date:3/2/2009

BROOMFIELD, Colo., March 2 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, today launched Axona(TM) in the United States for Alzheimer's disease (AD). Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's. Dispensed by prescription, it targets the metabolic deficiencies and imbalances associated with AD by providing an alternative energy source for brain cells.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/axona/36444/

Axona represents a new approach to helping manage AD symptoms and has been shown in clinical trials to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD.

"We are happy to have this new therapeutic approach to add to our management strategies for this terrible disease," said Jeffrey L. Cummings, M.D., Director, Mary S. Easton Center for Alzheimer's Disease Research at UCLA, and a consultant to Accera. "By approaching the disease in a new way, Axona addresses a metabolic abnormality of Alzheimer's disease that has not previously been examined. The goal of therapy is to optimize cognitive function. Axona is safe and can be used with other common therapies for Alzheimer's."

Alzheimer's disease is a progressive and fatal neurological disease characterized by a substantial decrease in the brain's ability to metabolize glucose, which is the brain's primary source of energy. Known as hypometabolism, this defect may contribute to both the clinical and pathological course of the disease. Axona targets the metabolic defects of glucose utilization in the brain by providing an alternative energy source. Axona is digested and metabolized by the liver to form keton
'/>"/>

SOURCE Accera
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. Video: Keppra XR(TM) Approved in the U.S.
10. Video: Fortune 1000 Executives: New President Must Fix Education Gap
11. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Laboratory (IL) today announced that their Strategic Alliance ... June 22, 2012, after more than twenty successful ... direct sales, service, support and marketing to end-user ... own Hemostasis product line, including the HemosIL® line ...
... Pharmaceuticals today announced that the United States Patent and ... entitled, "Antibodies specific to heterodimers of Bcl-2 family and ... method for extending Eutropics, BH3 profiling technology, which is ... technology assesses the ability of a key part of ...
... 2012  Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... an update on the progress of Sangamo,s ZFP Therapeutic® development ... the following conferences: , The 11th Annual JMP ... PT (6:00 pm ET), on Monday, May 14, 2012. ...
Cached Biology Technology:Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 2Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 3Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method 2Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... of a gene that optimizes their brain's thinking circuitry, ... severe mental illness marked by impaired thinking, scientists at ... Mental Health (NIMH) have discovered. The seeming paradox ... of variation in the human gene for a brain ...
... of epicatechin, a compound found in cocoa, are so striking ... importance to public health, reports Marina Murphy in Chemistry & ... medicine at Harvard Medical School, told C&I that epicatechin is ... , Hollenberg has spent years studying the benefits of cocoa ...
... Researchers from Université Laval’s Faculty of Medicine have ... antiwrinkle products causes a pathological reaction in skin ... present their conclusions about the mode of action ... the British Journal of Dermatology. , DMAE (2-dimethylaminoethanol) ...
Cached Biology News:Common gene version optimizes thinking -- but with a possible downside 2Cocoa 'vitamin' health benefits could outshine penicillin 2Anti-wrinkle compound causes pathological reaction in skin cells 2
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
DONOR BOVINE SERUM AND PLASMA...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: